

Michael R Johnson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5195378/publications.pdf>

Version: 2024-02-01

25
papers

1,032
citations

516710

16
h-index

610901

24
g-index

25
all docs

25
docs citations

25
times ranked

1979
citing authors

#	ARTICLE	IF	CITATIONS
1	Epigenomic priming of immune genes implicates oligodendroglia in multiple sclerosis susceptibility. <i>Neuron</i> , 2022, 110, 1193-1210.e13.	8.1	36
2	Assessing the role of rare genetic variants in drug-resistant, non-lesional focal epilepsy. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1376-1387.	3.7	16
3	Role of Common Genetic Variants for Drug-Resistance to Specific Anti-Seizure Medications. <i>Frontiers in Pharmacology</i> , 2021, 12, 688386.	3.5	6
4	A systems-level framework for anti-epilepsy drug discovery. <i>Neuropharmacology</i> , 2020, 170, 107868.	4.1	15
5	Pharmacoresponse in genetic generalized epilepsy: a genome-wide association study. <i>Pharmacogenomics</i> , 2020, 21, 325-335.	1.3	21
6	Testing association of rare genetic variants with resistance to three common antiseizure medications. <i>Epilepsia</i> , 2020, 61, 657-666.	5.1	22
7	Integrated systems-genetic analyses reveal a network target for delaying glioma progression. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1616-1638.	3.7	8
8	Comparative effectiveness of antiepileptic drugs in juvenile myoclonic epilepsy. <i>Epilepsia Open</i> , 2019, 4, 420-430.	2.4	34
9	A systems-level framework for drug discovery identifies Csf1R as an anti-epileptic drug target. <i>Nature Communications</i> , 2018, 9, 3561.	12.8	75
10	Genome-wide analysis of differential RNA editing in epilepsy. <i>Genome Research</i> , 2017, 27, 440-450.	5.5	73
11	Microglial positron emission tomography (PET) imaging in epilepsy: Applications, opportunities and pitfalls. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2017, 44, 42-47.	2.0	28
12	Standardization procedure for plasma biomarker analysis in rat models of epileptogenesis: Focus on circulating microRNAs. <i>Epilepsia</i> , 2017, 58, 2013-2024.	5.1	45
13	Meta-Analysis of MicroRNAs Dysregulated in the Hippocampal Dentate Gyrus of Animal Models of Epilepsy. <i>ENeuro</i> , 2017, 4, ENEURO.0152-17.2017.	1.9	23
14	Rare and common epilepsies converge on a shared gene regulatory network providing opportunities for novel antiepileptic drug discovery. <i>Genome Biology</i> , 2016, 17, 245.	8.8	75
15	Systems genetics identifies a convergent gene network for cognition and neurodevelopmental disease. <i>Nature Neuroscience</i> , 2016, 19, 223-232.	14.8	131
16	NRSF and BDNF polymorphisms as biomarkers of cognitive dysfunction in adults with newly diagnosed epilepsy. <i>Epilepsy and Behavior</i> , 2016, 54, 117-127.	1.7	19
17	MicroRNA profiles in hippocampal granule cells and plasma of rats with pilocarpine-induced epilepsy – comparison with human epileptic samples. <i>Scientific Reports</i> , 2015, 5, 14143.	3.3	101
18	Epileptic encephalopathy-causing mutations in <i>DNM1</i> impair synaptic vesicle endocytosis. <i>Neurology: Genetics</i> , 2015, 1, e4.	1.9	46

#	ARTICLE	IF	CITATIONS
19	EvoTol: a protein-sequence based evolutionary intolerance framework for disease-gene prioritization. Nucleic Acids Research, 2015, 43, e33-e33.	14.5	33
20	Systems genetics identifies Sestrin 3 as a regulator of a proconvulsant gene network in human epileptic hippocampus. Nature Communications, 2015, 6, 6031.	12.8	158
21	Validation of a multigenic model to predict seizure control in newly treated epilepsy. Epilepsy Research, 2014, 108, 1797-1805.	1.6	15
22	Newly diagnosed epilepsy and pharmacogenomics research: A step in the right direction?. Epilepsy and Behavior, 2011, 22, 3-8.	1.7	10
23	Heredity in epilepsy: Neurodevelopment, comorbidity, and the neurological trait. Epilepsy and Behavior, 2011, 22, 421-427.	1.7	40
24	Comment on "Blinders, phenotype, and fashionable genetic analysis: A critical examination of the current state of epilepsy genetic studies". Epilepsia, 2011, 52, 190-191.	5.1	2
25	Pharmacogenetic aspects. , 2005, , 26-44.		0